Skip to content
Blerp – Lifestyle
Author:
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 21, 2026
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026
Arrive AI Announces First Quarter 2026 Results and Highlights Operational Progress Toward Commercial Scale
May 15, 2026
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
Arrive AI Announces Fourth Quarter and Full-Year 2025 Results, Highlights Progress Toward Scaling Autonomous Delivery Network
April 15, 2026
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
←
Previous Page
1
2